spacer
home > events calendar > more about event
PHARMACEUTICAL INDUSTRY EVENTS CALENDAR

BIO-Europe 2018-24th Annual International Partnering Conference

5-7 November 2018
Bella Center Copenhagen, Denmark

BIO-Europe® is the preeminent partnering conference for the life sciences, bringing together international decision makers from the biotechnology, pharmaceutical and financial sectors, offering networking opportunities, workshop and panel participation, a high profile exhibition, and private, prescheduled one-to-one meetings.
 
Delegates from all parts of the biotechnology value chain come to BIO-Europe to quickly identify, engage and enter into strategic relationships that drive their businesses successfully forward. Investment and collaboration opportunities developed in prior BIO-Europe conferences have produced many highly successful business partnerships.
 
The BIO-Europe 2018 partnering event is expected to draw over 4,000 industry attendees for three days of high level networking, representing more than 2,000 companies from over 60 countries.

Partnering as an overall business strategy has transformed drug development in bringing together innovators and visionaries with seasoned experts from every corner of the globe. Partnering at BIO-Europe is powered by EBD Group’s partneringONE®, the industry’s most advanced networking system, which enables participants to efficiently mine a large pool of potential partners and pre-arrange private one-to-one meetings with dozens of company targets. The system—industry-specific, web-based and interactive—is uniquely suited for the needs of life science companies.

In addition to the program, two key elements at our partnering events are the presenting companies and the exhibition. At BIO-Europe, presenting companies are grouped into several tracks, including Biotech, Midsize Pharma, Next Generation, and Academic Innovators™. The high-exposure exhibition is the heart of the conference, and presents a prime opportunity to showcase products and services in a high-traffic location.
 
BIO-Europe is produced by EBD Group, the leading partnering firm for the global biotechnology industry, with the support of the Biotechnology Innovation Organization (BIO).

Speakers:https://ebdgroup.knect365.com/bioeurope/speakers

Program:https://ebdgroup.knect365.com/bioeurope/agenda/1


 
Print this page
Send to a friend
   
spacer
Industry Events

Clinical Trials Europe | Partnerships, Outsourcing, Operations & Technology

27 August - 21 November 2019, Barcelona, Spain

On 19-21 November 2019, the clinical trial community's most influential stakeholders will be meeting in Barcelona to discuss the evolving landscape, honing in on what it takes to harness true value from partnerships, outsourcing, operations, technology and early clinical development, for a faster, more efficient route to market.
More info >>

White Papers

The Role of the CRO in Effective Risk-Based Monitoring

Medpace

The clinical trial industry is evolving. In an effort to improve participant safety and data integrity, regulators are encouraging trial sponsors to transition from a focused on-site monitoring approach they have traditionally employed toward a risk-based approach that utilizes a combination of centralized and on-site monitoring techniques to ensure patient safety and data quality. The Risk-Based Monitoring (RBM) paradigm has many potential advantages over established monitoring practices including enhanced patient safety and data integrity, more efficient and effective protocol design, reduced costs, and the ability to strategically adjust oversight in keeping with changes in risk level.
More info >>


News and Press Releases

Sphere Fluidics Closes a $4.8 million USD (£3.7 million) Funding Round

Cambridge, UK, 10 June 2019: Sphere Fluidics, a company commercializing single cell analysis systems underpinned by its patented picodroplet technology, announced today that it has closed an additional tranche of investment of $2.9 million (£2.2 million), securing a total of $4.8 million (£3.7 million) in investment. The funding will be used as working capital for the Company’s Cyto-Mine® Single Cell Analysis System, expansion of the UK facility and enable the doubling of personnel through the opening of a new US Sales Office and Demo Lab in California.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement